ImmunityBio Lead Bladder Cancer Drug Trial Clears Power Check

All NewsMarch 26, 2026

ImmunityBio stock dips despite Anktiva trial validation, FDA ad warning, and bullish analyst targets amid strong year-to-date gains.

Importance Rank:

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.

Cookie settings ACCEPT

Manage consent